Additionally, to ascertain whether SRCIN1 is a potential drug target, validating its biological function through cell cycle arrest assays and apoptosis analysis is essential, especially in the context of SRCIN1-silenced, untreated and DAC-treated breast cancer cells. This evidence concerns the gene SRCIN1 and breast cancer.